Skip to main
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies is well-positioned for continued success due to their strong financials, strategic partnerships and successful pricing negotiations in the heme market. With a successful first quarter in 1Q26 and a successful strategy with multiple growth drivers, ADPT is expected to continue to experience strong revenue and volume growth in the future. Additionally, ADPT's strong financial outlook and raised projections further indicate their positive trajectory and potential for continued success in the biotech industry.

Bears say

Adaptive Biotechnologies is a company with strong potential in the growing field of immune-driven medicine, as seen through its FDA-approved diagnostic product, clonoSEQ, and its promising Immune Medicine platform. However, the company's financials show significant losses since inception and a reliance on milestone payments for its MRD segment, potentially suggesting a lack of sustainability or profitability. Furthermore, despite strong quarterly results, the stock has underperformed this year and faces potential risks such as slower customer adoption and reimbursement challenges. With a current premium valuation, there may be limited room for further upside in the stock price.

Adaptive Biotechnologies (ADPT) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 7 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.